Xconomy National

Archives

by in

Entry	Author	Date	Location
San Diego Life Sciences Roundup: Amylin, Optimer, and the Economy	Bruce V. Bigelow	02/03/12	San Diego
Angry at the Genome	Emily Walsh	01/25/12	Boston
In Life Sciences Partnerships, You Must be Smart from the Beginning	Bruce V. Bigelow	01/20/12	San Diego
A Good News-Bad News Night for Bristol’s Diabetes and Hepatitis Drugs	Arlene Weintraub	01/19/12	New York
Warp Drive Bio Launches With $125M from Third Rock, Greylock, Sanofi	Arlene Weintraub	01/10/12	Boston
Inspiration Bio Founders and Execs Inspired by New Boston Headquarters	Arlene Weintraub	01/04/12	Boston
Xconomy Storms NYC: Top Ten Topics in the Big Apple in 2011	Arlene Weintraub	12/27/11	New York
A Sweet Deal: How Amira Reinvented Itself as a Drug Discovery Engine	Bruce V. Bigelow	12/23/11	San Diego
The Move to Value-Based Pricing for Prescription Drugs	Michael Drummond	12/21/11	National
Cerulean Pharma Adds $15M to Further Nano-Drug Platform	Arlene Weintraub	12/15/11	Boston
Merck Chemists Use High-Tech Science to Combat Alzheimer’s Disease Challenge	Arlene Weintraub	12/14/11	New York
SF’s Prescience Sharpens New Biotech Business Model in San Diego	Bruce V. Bigelow	12/09/11	San Diego
Lpath Looks to Raise $10 Million Through Secondary Offering	Bruce V. Bigelow	12/08/11	San Diego
EnVivo Posts Positive Trial of Schizophrenia Drug	Arlene Weintraub	12/05/11	Boston
Fresh Off Amira Success, Versant’s Bolzon and San Diego’s Prasit Begin Anew with Inception	Bruce V. Bigelow	11/29/11	San Diego
Rib-X Pharma Files for IPO	Arlene Weintraub	11/28/11	Boston
ScaleVP’s Mitchell: FDA’s Capriciousness Is Driving Out Life Sciences Investors	Wade Roush	11/09/11	San Francisco
The Stroke Prevention War is On: FDA Approves J&J/Bayer Contender	Arlene Weintraub	11/07/11	New York
NPS Charts Positive Results on Parathyroid Drug	Arlene Weintraub	11/07/11	New York
Xconomists of the Week: Tom Maniatis and Marc Tessier-Lavigne Lead the Charge on the New York Genome Center	Arlene Weintraub	11/03/11	New York
NPS Pharma’s Not-So-Excellent Wall Street Adventure	Arlene Weintraub	11/03/11	New York
New York Genome Center to Open in February, Supported by $125M in Public and Private Funding	Arlene Weintraub	11/02/11	New York
Cubist Says Adolor Deal Offers “Free Option on Billion-Dollar Program”	Arlene Weintraub	10/26/11	Boston
Life Sciences 2031: What about 2011?	David Sable	10/20/11	New York
Merck Fine-Tunes Biosimilars Strategy as FDA Guidelines Loom	Arlene Weintraub	10/05/11	New York
Backed by Eclectic Financiers, Acetylon Begins Trials of Cancer Drug	Arlene Weintraub	09/27/11	Boston
San Diego’s Afraxis Gets NIH Support to Develop Compound for Rare Fragile X Syndrome	Bruce V. Bigelow	09/26/11	San Diego
Latest in Stroke-Prevention Saga: FDA Panel Backs Drug From J&J and Bayer	Arlene Weintraub	09/09/11	New York
Bristol-Pfizer Team on Alert as FDA Reviews Stroke-Prevention Drug From Rivals J&J and Bayer	Arlene Weintraub	09/08/11	New York
Repligen Seeks Approval for Imaging Product While Pursuing Rare-Disease Drugs and Manufacturing Platform	Arlene Weintraub	09/01/11	Boston
Page 1 of 9	next page »